Alpha-reductase mRNA Research Articles

Adenosine 5'-Monophosphate-Activated Protein Kinase Regulates 5 alpha-Reductase mRNA Expression in Ovarian Granulosa Cells.

Adenosine 5'-Monophosphate-Activated Protein Kinase Regulates 5 alpha-Reductase mRNA Expression in Ovarian Granulosa Cells.

Elevation of steroid 5 alpha-reductase mRNA levels in rat cerebellum by toluene inhalation: possible relation to GFAP expression.

Toluene, a commonly used industrial solvent, is known to be toxic to both neuronal and glial cells, and has been shown to increase the immunoreactivity of glial fibrillary acidic protein (GFAP) in the brain. However, the mechanism of toluene-induced GFAP expression is poorly understood. Recently, GFAP mRNA expression in cultured astrocytes has been shown to be modulated by various steroid hormones, such as progesterone, testosterone, and their 5 alpha-reduced metabolites. Therefore, it seems possible that steroid hormones may play a potential role in the enhancement of GFAP expression observed following toluene exposure. To address this possibility, the effect of toluene inhalation on the expression of mRNAs encoding GFAP and steroidogenic enzymes in rat brain was examined. Toluene exposure increased GFAP protein contents without any significant alteration in GFAP mRNA levels in the hippocampus. In contrast, the elevation of both GFAP protein contents and its mRNA levels was observed in the cerebellum following toluene exposure. Further studies indicated that toluene exposure increased steroid 5 alpha-reductase (5 alpha-R) mRNA levels prior to the elevation of GFAP mRNA in the cerebellum, whereas neither 5 alpha-R nor GFAP mRNA levels in the hippocampus were significantly affected by toluene exposure. These results suggest that toluene inhalation may enhance GFAP gene expression in the rat cerebellum, and propose the possibility that the elevation of 5 alpha-R expression, and hence 5 alpha-reduced metabolites of steroid hormones, is presumably related to toluene-induced GFAP mRNA expression.

Expression of androgen-activating enzymes in cultured cells of developing rat brain.

Dihydrotestosterone and estradiol, two active metabolites formed locally in the brain from testosterone, modulate several functions of the developing rat CNS; these compounds derive from the 5 alpha-reduction or the aromatization of the A-ring of the hormone. Also, progesterone and corticosteroids may be 5 alpha-reduced and subsequently 3 alpha-hydroxylated, becoming modulators of specific neuronal functions. Although the aromatase is a single enzyme, two types of 5 alpha-reductase have been cloned, showing peculiar biochemical properties and probably different functions. Therefore, the isoform(s) of the enzyme 5 alpha-reductase(s) present in early stage of brain development have been characterized in primary neuronal and glial cell cultures obtained from the fetal or neonatal rat brain, respectively. Aromatase expression was also studied. The results have shown that in all the brain cells examined type 1 5 alpha-reductase mRNA is expressed. No specific transcript of type 2 5 alpha-reductase is detectable in any of the cell types examined. Finally, the aromatase gene is expressed only in cultured fetal neurons and especially in those derived from the hypothalamic area of the rat embryos. It is interesting that no aromatase mRNA is detectable in mixed glia or in type 1 astrocytes and oligodendrocytes cultured separately.

Steady state steroid 5 alpha-reductase messenger ribonucleic acid levels and immunocytochemical localization of the type 1 protein in the rat testis during postnatal development.

Steroid 5 alpha-reductase is the rate-limiting enzyme in the production of 5 alpha-reduced steroids in many tissues. Developmental changes in 5 alpha-reductase activity play an important role in regulating the amount of testosterone that is secreted by the testis. To date, the regulation of testicular 5 alpha-reductase has been studied extensively at the level of enzyme activity. Regulation at the messenger RNA (mRNA) and protein levels, however, has not been investigated. The objectives of the present study were to determine the steady state mRNA levels for the 5 alpha-reductase isozymes, types 1 and 2, and to immunolocalize the 5 alpha-reductase type 1 protein in the developing rat testis (7-91 days postpartum). Consistent with previously reported enzyme activity studies, type 1 5 alpha-reductase mRNA levels were most abundant in the immature animal (days 21-28). Unlike 5 alpha-reductase activity, however, type 1 mRNA levels did not decline thereafter to reach nearly undetectable levels in the adult (day 91). In contrast, 5 alpha-reductase type 1 mRNA levels remained relatively constant between days 42-91. The 5 alpha-reductase type 1 transcript size did not remain constant during postnatal testicular development. The characteristic 2.5-kilobase type 1 transcript size was detected in immature rats (days 21-28), whereas in the adult (day 91), a slower migrating 2.7-kilobase type 1 mRNA species was observed. An antipeptide antiserum specific to rat 5 alpha-reductase type 1 was used to immunolocalize the 5 alpha-reductase type 1 protein. At all ages examined, the immunoperoxidase reaction was localized predominantly to the interstitial tissue of the testis. On postnatal day 7, clusters of interstitial cells resembling fetal Leydig cells were clearly immunoreactive. The staining intensity increased steadily from day 7 onwards, so that by days 21 and 28, interstitial cells with the appearance of immature Leydig cells were intensely immunoreactive (peak expression). This was followed by a progressive decrease in staining intensity between days 28-91, so that by day 91 (adult) Leydig cell immunoreactivity was barely detectable. Immunocytochemical staining revealed a predominantly cytoplasmic localization; significant nuclear staining was not evident. We conclude that the expression of the 5 alpha-reductase type 1 protein is primarily found in the cytoplasm of Leydig cells, is dependent on age, and that this expression closely parallels 5 alpha-reductase enzyme activity.

Growth hormone directly affects the function of the different lobes of the rat prostate.

In this study, we investigated the involvement of GH in rat prostate function. First, we demonstrated that specific transcripts corresponding to the GH receptor (4.5 kilobases) and to the GH-binding protein (1.2 kilobases) were expressed in the normal rat prostate, but also in all prostatic carcinoma cell lines tested (LNCaP, PC-3, MAT-Lu, MAT-LyLu, and Pif-1). Moreover, these transcripts were much more abundant in the human and rat carcinoma cells than in the normal tissue. One-year-old dwarf rats were supplemented for 7 days with saline (group DR1) or highly purified rat GH (group DR2). Northern blotting and quantitation of prostatic messenger RNAs (mRNAs) revealed that GH increases the steady state levels of transcripts coding for androgen receptor (2.4-fold), type I and II 5 alpha-reductases (2.6- and 2.2-fold), and several androgen-dependent proteins [prostatein C3 subunit (3.6-fold), probasin (11.0-fold), and R. W. B. (Royal Winnipeg Ballet) (12.5-fold)]. This suggests that GH might either potentiate the action of androgens on the prostate or act directly on this gland by a mechanism that does not depend on testicular androgens. To address this question, we supplemented hypophysectomized and castrated adult rats for 7 days with saline (group HC1), rat GH (group HC2), testosterone propionate (group HC3), or GH plus testosterone (group HC4), starting 3 days after castration. In this animal model, the abundance of C3 mRNA increased in all hormone-treated rats; the stimulation factors were 3.5 (group HC2), 25.5 (group HC3), and 9.5 (group HC4) compared to group HC1. Analysis of prostatein synthesis by Western blotting confirmed these results at the protein level. The same trend was observed for probasin and RWB mRNA levels. Probasin mRNA increased 4.5-fold in group HC2 and 12-fold in group HC3, but did not increase in group HC4 (both hormones combined); enhancement of RWB mRNA was, respectively, 5.0-, 28.0-, and 15.0-fold in groups HC2, HC3, and HC4. GH did not affect the abundance of androgen receptor mRNA. As described previously, the level of this mRNA dropped significantly in group HC3. GH alone did not significantly alter the level of either 5 alpha-reductase mRNA, whereas testosterone, alone or with GH, produced a 2-fold increase in type II 5 alpha-reductase mRNA (groups HC3 and HC4). Type I isoenzyme mRNA reached 1.6 times the control level (group HC1) in groups HC3 and HC4.(ABSTRACT TRUNCATED AT 400 WORDS)

Growth hormone directly affects the function of the different lobes of the rat prostate

In this study, we investigated the involvement of GH in rat prostate function. First, we demonstrated that specific transcripts corresponding to the GH receptor (4.5 kilobases) and to the GH-binding protein (1.2 kilobases) were expressed in the normal rat prostate, but also in all prostatic carcinoma cell lines tested (LNCaP, PC-3, MAT-Lu, MAT-LyLu, and Pif-1). Moreover, these transcripts were much more abundant in the human and rat carcinoma cells than in the normal tissue. One-year-old dwarf rats were supplemented for 7 days with saline (group DR1) or highly purified rat GH (group DR2). Northern blotting and quantitation of prostatic messenger RNAs (mRNAs) revealed that GH increases the steady state levels of transcripts coding for androgen receptor (2.4-fold), type I and II 5 alpha-reductases (2.6- and 2.2-fold), and several androgen-dependent proteins [prostatein C3 subunit (3.6-fold), probasin (11.0-fold), and R. W. B. (Royal Winnipeg Ballet) (12.5-fold)]. This suggests that GH might either potentiate the action of androgens on the prostate or act directly on this gland by a mechanism that does not depend on testicular androgens. To address this question, we supplemented hypophysectomized and castrated adult rats for 7 days with saline (group HC1), rat GH (group HC2), testosterone propionate (group HC3), or GH plus testosterone (group HC4), starting 3 days after castration. In this animal model, the abundance of C3 mRNA increased in all hormone-treated rats; the stimulation factors were 3.5 (group HC2), 25.5 (group HC3), and 9.5 (group HC4) compared to group HC1. Analysis of prostatein synthesis by Western blotting confirmed these results at the protein level. The same trend was observed for probasin and RWB mRNA levels. Probasin mRNA increased 4.5-fold in group HC2 and 12-fold in group HC3, but did not increase in group HC4 (both hormones combined); enhancement of RWB mRNA was, respectively, 5.0-, 28.0-, and 15.0-fold in groups HC2, HC3, and HC4. GH did not affect the abundance of androgen receptor mRNA. As described previously, the level of this mRNA dropped significantly in group HC3. GH alone did not significantly alter the level of either 5 alpha-reductase mRNA, whereas testosterone, alone or with GH, produced a 2-fold increase in type II 5 alpha-reductase mRNA (groups HC3 and HC4). Type I isoenzyme mRNA reached 1.6 times the control level (group HC1) in groups HC3 and HC4.

Tyrosine kinase inhibitor AG18 arrests follicle-stimulating hormone-induced granulosa cell differentiation: use of reverse transcriptase-polymerase chain reaction assay for multiple messenger ribonucleic acids.

A sensitive assay of multiple mRNAs by reverse transcriptase-polymerase chain reaction was adopted to study the hormonally regulated expression of steroidogenic enzymes in primary rat granulosa cells in culture. As little as 15-60 ng total RNA prepared from cultured cells were reverse transcribed in the presence of pd(T)6, and polymerase chain reaction was conducted in the presence of specific oligonucleotide pairs designed to identify cDNAs of steroidogenic enzymes. In combination with Northern blot analysis of cholesterol side-chain cleavage cytochrome P450 (P450scc) message, it is shown that a novel protein kinase inhibitor, tyrphostin AG18, arrests the FSH-induced accumulation of P450scc mRNA. This inhibition is dose dependent (IC50, 15 microM) and reversible. The addition of 80 microM AG18 to cells containing high levels of P450scc mRNA caused a rapid decline of the cytochrome message (t 1/2, 5 h), similar to the effect of 30 micrograms/ml alpha-amanitin. However, concomitant addition of the two drugs did not accelerate the mRNA degradation process, suggesting that AG18 does not affect message stabilization. Tyrphostin AG18 did not affect mRNA species that are not FSH inducible, such as the ribosomal protein L19, or the constitutively expressed low levels of steroid 5 alpha-reductase mRNA. Moreover, even the extremely high levels of P450scc mRNA in granulosa-lutein cells, being cAMP independent and terminally differentiated a few hours after LH surge, were not affected by the addition of AG18 in culture. In contrast, two additional key and FSH-inducible steroidogenic enzymes, i.e. aromatase cytochrome P450 and 3 beta-hydroxysteroid dehydrogenase-I, were inhibited by AG18 at their mRNA levels. These results suggest that an as yet undetermined tyrosine kinase pathway is involved in the cAMP-dependent signal transduction pathway of FSH action, so that the presence of AG18 does not allow FSH induction of gene expression to occur.

Expression of 4-ene steroid 5 alpha-reductase messenger ribonucleic acid in the rat epididymis during postnatal development

The regulation of epididymal 5 alpha-reductase mRNA is multifactorial and segment-specific. To further investigate the regulation of the message for the enzyme, the expression of 5 alpha-reductase mRNA in the rat epididymis was studied as a function of postnatal development. Developmental changes in 5 alpha-reductase mRNA concentrations were assessed by probing Northern blots with the full-length cDNA for rat steroid 5 alpha-reductase. In the first experiment the effect of postnatal age on 5 alpha-reductase mRNA concentrations in the caput-corpus and cauda epididymides was studied. Male rats, taken at 1-week intervals between the ages of 7-91 days, were used. In both epididymal regions, the mRNA for 5 alpha-reductase was present at all ages examined; it appeared in the immature animal at least 2 weeks before detectable 5 alpha-reductase enzyme activity. In the caput-corpus epididymidis, mRNA levels for 5 alpha-reductase decreased by half between postnatal days 7 and 21, rose 5-fold by day 56, and then remained constant through day 91. No change with postnatal age, however, was observed in the cauda epididymidis. In the second experiment, the longitudinal distribution of 5 alpha-reductase mRNA on postnatal days 21, 42, 49, 56, 77, and 91 was studied. The mRNA levels for 5 alpha-reductase increased remarkably, by 6- to 7-fold, in the initial segment of the caput epididymidis between postnatal days 21 and 42 and stayed constant thereafter. However, no significant change comparable to that found in the initial segment was observed in the adjacent proximal caput region or in any of the other epididymal segments. Thus, the 5-fold rise in 5 alpha-reductase mRNA concentrations that occurred in the caput-corpus epididymidis in the first experiment can be attributed solely to changes in the initial segment. We conclude that steady state concentrations of epididymal 5 alpha-reductase mRNA vary dramatically at different postnatal ages and are highly specific with respect to epididymal segment.

Expression of 4-ene steroid 5 alpha-reductase messenger ribonucleic acid in the rat epididymis during postnatal development.

The regulation of epididymal 5 alpha-reductase mRNA is multifactorial and segment-specific. To further investigate the regulation of the message for the enzyme, the expression of 5 alpha-reductase mRNA in the rat epididymis was studied as a function of postnatal development. Developmental changes in 5 alpha-reductase mRNA concentrations were assessed by probing Northern blots with the full-length cDNA for rat steroid 5 alpha-reductase. In the first experiment the effect of postnatal age on 5 alpha-reductase mRNA concentrations in the caput-corpus and cauda epididymides was studied. Male rats, taken at 1-week intervals between the ages of 7-91 days, were used. In both epididymal regions, the mRNA for 5 alpha-reductase was present at all ages examined; it appeared in the immature animal at least 2 weeks before detectable 5 alpha-reductase enzyme activity. In the caput-corpus epididymidis, mRNA levels for 5 alpha-reductase decreased by half between postnatal days 7 and 21, rose 5-fold by day 56, and then remained constant through day 91. No change with postnatal age, however, was observed in the cauda epididymidis. In the second experiment, the longitudinal distribution of 5 alpha-reductase mRNA on postnatal days 21, 42, 49, 56, 77, and 91 was studied. The mRNA levels for 5 alpha-reductase increased remarkably, by 6- to 7-fold, in the initial segment of the caput epididymidis between postnatal days 21 and 42 and stayed constant thereafter. However, no significant change comparable to that found in the initial segment was observed in the adjacent proximal caput region or in any of the other epididymal segments. Thus, the 5-fold rise in 5 alpha-reductase mRNA concentrations that occurred in the caput-corpus epididymidis in the first experiment can be attributed solely to changes in the initial segment. We conclude that steady state concentrations of epididymal 5 alpha-reductase mRNA vary dramatically at different postnatal ages and are highly specific with respect to epididymal segment.

Differential Regulation of Steady State 4-Ene Steroid 5α-Reductase Messenger Ribonucleic Acid Levels along the Rat Epididymis*

Epididymal nuclear 5 alpha-reductase enzyme activity is regulated by a testosterone-dependent factor from the testis. Regulation at the mRNA level, however, has not been investigated. Endocrine manipulation experiments were designed to determine whether 5 alpha-reductase is regulated at the steady state mRNA level. Steady state mRNA concentrations were assessed using the full-length cDNA for female rat liver 5 alpha-reductase. Longitudinal distribution showed that the highest mRNA concentrations were present in the initial segment of the caput epididymidis and were 3- to 7-fold higher than in the other tissue segments. The androgen dependence of the mRNA levels for 5 alpha-reductase was assessed by bilateral orchidectomy and simultaneous testosterone replacement therapy. One week after surgery, mRNA concentrations in orchidectomized rats were decreased to 15% of control levels in the initial segment of the caput epididymidis and to 40-50% of control levels in the remaining epididymal segments. Administration of testosterone at a dose that mimics normal serum concentrations (2.5-cm Silastic implant) restored 5 alpha-reductase mRNA concentrations to control levels in the corpus and cauda epididymidis, but these were not significantly different from orchidectomized levels (P greater than or equal to 0.05) in the initial segment and caput epididymidis. Administration of testosterone at a dose designed to approximate 5- to 8-fold normal serum concentrations (18.6-cm implant) maintained 5 alpha-reductase mRNA concentrations at only 50% of control levels in the initial segment, while complete maintenance was observed in the rest of the tissue. The effects of unilateral orchidectomy revealed that 5 alpha-reductase mRNA concentrations decrease selectively in the initial segment of the orchidectomized side. This is the first report that epididymal 5 alpha-reductase is regulated at the mRNA level and that the regulation is different with respect to the segment being studied.

Expression of Neural 5α-Reductase Messenger Ribonucleic Acid: Comparison to 5α-Reductase Activity during Prenatal Development in the Rat*

The present study was designed to characterize the developmental pattern of 5 alpha-reductase messenger RNA (mRNA) levels and enzyme activity in intact medial basal hypothalamic (MBH) and preoptic area (POA) tissue fragments of rats during fetal development. 5 alpha-Reductase activity was determined using [3H]testosterone as the substrate and quantifying, by TLC, the radiolabeled 5 alpha-reduced metabolites (dihydrotestosterone [DHT] and 5 alpha-androstane-3 alpha,17 beta-diol). Confirmation of the identity of the [3H]5 alpha-DHT formed was demonstrated by recrystallization of the derivatized DHT to constant specific activity. Under saturating substrate conditions (1.7 microM testosterone), there were no significant sex differences (male vs. female) detected in neural 5 alpha-reductase during prenatal, perinatal, or neonatal development. 5 alpha-Reductase activity was low but detectable at gestational day (GD) 15 (approximately 10 pmol/h.mg protein), increased over 3-fold to peak levels at GD 18, and then declined to moderate levels at GD 22 (approximately 22 pmol/h.mg protein) and 4 days after birth (approximately 17 pmol/h.mg protein). In addition, the developmental pattern of 5 alpha-reductase mRNA expression in fetal MBH-POA tissue was determined, by RNA blot hybridization, using a complementary DNA encoding the rat 5 alpha-reductase enzyme. A single mRNA species was detected at 2.5 kilobase in MBH-POA tissue, which is similar in size to adult rat liver and prostate 5 alpha-reductase mRNA. At GD 15, 5 alpha-reductase mRNA was clearly detectable; the abundance increased on GD 17, remained at maximal levels at GDs 18, 19, and 20, and then decreased to moderate levels on GD 22. A correlation calculated between the normalized 5 alpha-reductase mRNA levels and enzyme activities revealed a strong correspondence between mRNA abundance and enzyme activity values during prenatal development, r = 0.80, P = 0.056. These findings indicate that neural 5 alpha-reductase activity may be developmentally regulated, and that the changes in 5 alpha-reductase activity in MBH-POA tissue during late fetal development are regulated, in part, by the levels of mRNA encoding the 5 alpha-reductase enzyme.

Biosynthesis of catalytically active rat testosterone 5 alpha-reductase in microinjected Xenopus oocytes: evidence for tissue-specific differences in translatable mRNA.

The enzyme 4-ene-3-ketosteroid-5 alpha-oxidoreductase [5 alpha-reductase; 3-oxo-5 alpha-steroid delta 4-dehydrogenase, 3-oxo-5 alpha-steroid: (acceptor) delta 4-oxidoreductase, EC 1.3.99.5] plays a key role in androgen-dependent target tissues, where it catalyzes the conversion of testosterone to the biologically active dihydrotestosterone. The regulation of 5 alpha-reductase expression has not been studied at the molecular level as the enzyme is a membrane protein that is labile in cell-free homogenates. We developed a sensitive bioassay of the enzyme activity expressed in Xenopus oocytes microinjected with rat liver and prostate mRNA. After microinjection, incubation of intact oocytes in the presence of [3H]testosterone revealed the in ovo appearance of active 5 alpha-reductase. Polyadenylated RNA was fractionated by sucrose gradient centrifugation, and the enzymatic activity was shown to be encoded by a 1600- to 2000-base-pair fraction of hepatic poly(A)+ RNA. 5 alpha-Reductase mRNA was most efficiently translated when up to 80 ng of RNA was injected per oocyte. In the injected oocytes, 5 alpha-reductase mRNA was found to be a short-lived molecule (t1/2 = 2 hr), whereas its in ovo translatable 5 alpha-reductase protein exhibited stable enzymatic activity for over 40 hr. Moreover, the levels of translatable tissue-specific 5 alpha-reductase mRNAs as monitored in the Xenopus oocytes correlated with the variable 5 alpha-reductase activities in female rat liver, male rat liver, and prostate homogenates; the ratio of their specific activities was of 2500:630:1, respectively. Altogether, these results provide supporting evidence in favor of the transcriptional control of 5 alpha-reductase expression in rat tissues.